| Outcome Measures: |
Primary: C-peptide level, incremental AUC over 120 minutes during the MMTT at Day 112 compared to baseline (Day 0 pre-dose | Secondary: Change in insulin requirements, 3-day average daily insulin dose at baseline (Day -3 through Day -1) compared to Day 112 (Day 109 through Day 111)|HbA1c levels, from baseline (Day 0 pre-dose) at Day 112|fasting glucose, from baseline (Day 0 pre-dose) at Day 112|fasting glucagon, from baseline (Day 0 pre-dose) at Day 112|cortisol, from baseline (Day 0 pre-dose) at Day 112|markers of systemic inflammation (Interleukin-6, Interleukin-8, Tumor Necrosis Factor α, hs-CRP), from baseline (Day 0 pre-dose) at Day 112|adipokines, from baseline (Day 0 pre-dose) at Day 112|meal-stimulated Glucagon like peptide-1, AUC over 120 minutes at Day 112 compared to baseline (Day 0 pre-dose)|meal-stimulated gastric inhibitory polypeptide, AUC over 120 minutes at Day 112 compared to baseline (Day 0 pre-dose)|lipids profile, from baseline (Day 0 pre-dose) at Day 112|Change in fatigue according to the Fatigue Scale for Motor and Cognitive Functions (FSMC) questionnaire, from baseline at Day 112|Anti XOMA 052 Antibodies, from baseline (Day 0 pre-dose) at Day 112|Number of Adverse Events, from baseline (Day 0 pre-dose) at Day 364
|
